Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00101413 · BASELINE

Baseline characteristics

BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC) · Source last updated 2013-10-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      52
    units
    Participants
groups
  1. description
    Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (bid, bis in die) X 28 day cycles
    id
    BG000
    title
    Sorafenib
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          26
          upper Limit
          85
          value
          62
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          21
      title
      >=65 years
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          31
      title
      < 65 years
    param Type
    NUMBER
    title
    Age, Customized
    unit Of Measure
    participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          18
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          34
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  4. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          28
      title
      Adenocarcinoma NSCLC
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          4
      title
      Large cell carcinoma
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          16
      title
      Squamous cell (epidermoid) carcinoma
    4. categories
      1. measurements
        1. group Id
          BG000
          value
          4
      title
      Undifferentiated carcinoma
    description
    Measurable, histologically or cytologically documented stage IV non-small cell lung cancer (NSCLC). Subjects must have had disease progression at the time of study entry and have been treated with at least 1 but no more than 2 prior systemic agents or regimens (including gefitinib).
    param Type
    NUMBER
    title
    Histology
    unit Of Measure
    participants
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      52
    units
    Participants
groups
  1. description
    Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (bid, bis in die) X 28 day cycles
    id
    BG000
    title
    Sorafenib
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          26
          upper Limit
          85
          value
          62
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          21
      title
      >=65 years
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          31
      title
      < 65 years
    param Type
    NUMBER
    title
    Age, Customized
    unit Of Measure
    participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          18
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          34
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  4. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          28
      title
      Adenocarcinoma NSCLC
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          4
      title
      Large cell carcinoma
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          16
      title
      Squamous cell (epidermoid) carcinoma
    4. categories
      1. measurements
        1. group Id
          BG000
          value
          4
      title
      Undifferentiated carcinoma
    description
    Measurable, histologically or cytologically documented stage IV non-small cell lung cancer (NSCLC). Subjects must have had disease progression at the time of study entry and have been treated with at least 1 but no more than 2 prior systemic agents or regimens (including gefitinib).
    param Type
    NUMBER
    title
    Histology
    unit Of Measure
    participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice